ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    remarc
Previous Study | Return to List | Next Study

Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP (REMARC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01122472
Recruitment Status : Active, not recruiting
First Posted : May 13, 2010
Last Update Posted : March 12, 2018
Sponsor:
Information provided by (Responsible Party):
The Lymphoma Academic Research Organisation

Brief Summary:

This study is designed as a phase III, randomized, double-blind, placebo-controlled trial to explore the effect of maintenance therapy with lenalidomide versus placebo on progression-free survival (PFS) in patients treated with R-CHOP responding to induction therapy

For the primary efficacy variable, PFS, an improvement in median PFS from 38.6 months for Treatment Arm B to 54 months for Treatment Arm A (corresponding to a 2-year PFS of 65% vs 73.6%), is considered clinically relevant.


Condition or disease Intervention/treatment Phase
Lymphoma Diffuse Large B-cell Lymphoma Drug: Lenalidomide Drug: Placebo Phase 3

Detailed Description:

Patients should have received at least 6 and up to 8 cycles of the R-CHOP 14 or R-CHOP 21 regimen or 6 R-CHOP-14 or -21 completed by 2 Rituximab alone in accordance to local preferences.

Patients can be registered to participate in the study at two time points:

  • At time of initial diagnosis and study enrolment (signature of informed consent) before the first cycle of treatment with R-CHOP.
  • At randomization (signature of informed consent) after treatment in first line with R-CHOP and have reached at least PR or CR.

Evaluation of the response to R-CHOP must be in accordance with Revised Response Criteria for Malignant Lymphoma(2007).

Stratification: Before randomization, the patients will be stratified according to the country and the response to R-CHOP (PR vs CR).

Randomization: Patients in CR/PR after R-CHOP will be randomized to maintenance therapy with lenalidomide or placebo.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 650 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Double Blind Randomized Phase III Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP in First Line
Study Start Date : April 2009
Actual Primary Completion Date : June 2016
Estimated Study Completion Date : September 2019


Arm Intervention/treatment
Experimental: Lenalidomide
Lenalidomide daily for 3 weeks every 4 weeks for 24 months
Drug: Lenalidomide
Daily for 3 weeks every 4 weeks for 24 months
Other Name: Revlimid

Placebo Comparator: Placebo
Placebo daily for 3 weeks every 4 weeks for 24 months
Drug: Placebo
Daily for 3 weeks every 4 weeks for 24 months




Primary Outcome Measures :
  1. Progression-Free-Survival (PFS) [ Time Frame: Final PFS analysis will be realized when the number of events (160) has been reached or at the latest when the last patient into the study will finish follow up. The approximate schedule will be 75 months after the first patient randomized. ]
    PFS will be measured from the date of randomization to the date of first documented disease progression or death. Progression data will be assigned to the earliest time when any progression is observed without prior missing assessments during the study up to the end of the follow up phase.


Secondary Outcome Measures :
  1. Overall survival (OS) [ Time Frame: 5 years ]
    From the date of randomization to the date of death from any cause Interim analysis of OS will be performed at the time of the PFS final analysis; it is projected to have 97 deaths at this time. Final analysis of OS at the end of the study, defined by the last visit of follow-up for the last patient randomized, 5 years after its randomization

  2. Event-Free Survival (EFS) [ Time Frame: 5 years ]
    From the date of randomization to the date of first documented disease progression, relapse, initiation of new anti-lymphoma therapy or death from any cause Interim analysis of EFS will be performed at the time of the PFS final analysis. Final analysis of OS at the end of the study, defined by the last visit of follow-up for the last patient randomized, 5 years after its randomization

  3. Response rate at the end of maintenance treatment [ Time Frame: 24 months ]
  4. Percentage of patients who convert from PR (partial response) to CR (complete response) [ Time Frame: 24 months ]
  5. Safety of lenalidomide in maintenance [ Time Frame: 5 years ]
    Toxicities occured during maintenance phase will be measured and reported from grade 2 for infection and neurological toxicities and from grade 3 for other toxicities according to CTCAE v3

  6. PFS2 [ Time Frame: 5 years ]
    From randomization to objective tumor progression on next-line treatment or death from any cause



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   60 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Ages Eligible for Study: Between 60 and 80 years old

Genders Eligible for Study: Both

Accepts Healthy Volunteers: No

Inclusion Criteria:

For patients registered at the time of initial diagnosis

  • Patient with histologically proven CD20+ diffuse large B cel LYMPHOMA (DLBCL) 5WHO classification 2008) including clinical subtypes (primitive mediastinal, intravascular, etc.). Patients with De Novo Transformed DLBCL from low grade lymphoma (Follicular, other..) may also be included. Patients with DLBCL associated with some small cell infiltration in bone marrow may also be included Or CD20+ B-cell lymphoma with intermediate features between DLBCL and Burkitt or with intermediate features between DLBCL and classical Hodgkin lymphoma Or CD20+ Follicular lymphoma grade 3B Or CD20+ Aggressive B-cell lymphoma unclassifiable
  • previous untreated with chemo- or radiotherapy

For patients registered after response evaluation to first line treatment with R-CHOP:

  • Patient with histologically proven CD20+ diffuse large B cell LYMPHOMA (DLBCL) 5WHO classification 2008) including clinical subtypes (primitive mediastinal, intravascular, etc.). Patients with De Novo Transformed DLBCL from low grade lymphoma (Follicular, other..) may also be included. Patients with DLBCL associated with some small cell infiltration in bone marrow may also be included Or CD20+ B-cell lymphoma with intermediate features between DLBCL and Burkitt or with intermediate features between DLBCL and classical Hodgkin lymphoma Or CD20+ Follicular lymphoma grade 3B Or CD20+ Aggressive B-cell lymphoma unclassifiable
  • Have reached a CR or PR after first line treatment with at least 6 cycles of R-CHOP 14 regimens and up to 8 cycles of R-CHOP21
  • Previously untreated with Radiotherapy

For all patients:

  • aged from 60 to 80 years at time of registration
  • Ann Arbor stages II-IV at time of initial diagnosis
  • aaIPI> 1 at time of initial diagnosis
  • ECOG performance status 0-2
  • Minimum life expectancy of 3 months
  • Following laboratory values at screening:

    • ANC≥ 1000.10^6/L and Platelets≥60000.10^6/L
    • AST<5*ULN, ALT<5*ULN, Total Bilirubin<1,5*ULN
    • Creatinine clearance>30mL/min
  • Women are are using effective contraception, are not pregnant and agree not to become pregnant during participation in the trial and after end of study. Men agree not to father a child during participation in the trial and during the 12 months thereafter.
  • Having previously signed a written informed consent form

Exclusion Criteria:

  • Any other histological type of Lymphoma, Burkitt included.
  • Any history of treated or non treated small B-cell lymphoma
  • Central nervous system or meningeal involvement by lymphoma
  • Contraindication to any drug contained in the chemotherapy regimen Myocardial infarction during last 3 months or unstable coronary disease or uncontrolled chronic symptomatic congestive heart insufficiency NYHA III-IV
  • Uncontrolled hypertension
  • Uncontrolled diabetes mellitus as defined by the investigator
  • Active systemic infection requiring treatment
  • previously known HIV positive serology
  • Active hepatitis B or C
  • Prior history of malignancies other than lymphoma within 3 years
  • Serious medical or psychiatric illness

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01122472


  Show 157 Study Locations
Sponsors and Collaborators
The Lymphoma Academic Research Organisation
Investigators
Principal Investigator: Bertrand COIFFIER, Prof The Lymphoma Study Association (LYSA)

Additional Information:
Responsible Party: The Lymphoma Academic Research Organisation
ClinicalTrials.gov Identifier: NCT01122472     History of Changes
Other Study ID Numbers: REMARC
First Posted: May 13, 2010    Key Record Dates
Last Update Posted: March 12, 2018
Last Verified: March 2018

Keywords provided by The Lymphoma Academic Research Organisation:
lenalidomide (Revlimid)
diffuse large B-cell lymphoma
phase III study
after R-CHOP
Maintenance treatment
Maintenance

Additional relevant MeSH terms:
Lymphoma
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Lenalidomide
Thalidomide
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents
Immunosuppressive Agents
Leprostatic Agents
Anti-Bacterial Agents
Anti-Infective Agents